Aimmune Therapeutics   Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: San Mateo CA United States (2011)
Status: Acquired by Nestle (2020)

Organization Overview

First Clinical Trial
2014
NCT01987817
First Marketed Drug
2020
peanut allergen (Palforzia)
First NDA Approval
2020
peanut allergen (Palforzia)
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Aimmune Therapeutics | Aimmune Therapeutics, Inc.

Active Ingredients

Marketed Drugs (1)

peanut allergen (Palforzia) (2020 NDA)

Drugs in Phase 3 Trials (2)

ar101 (Aerumab) (9 trials)

peanut allergen (Palforzia) (1 trial)

Drugs in Phase 2 Trials (3)

ar201 (1 trial)

dupilumab (dupixent) (1 trial)

peanut (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Egg Hypersensitivity (Phase 2)

Hypersensitivity (Phase 3)

Peanut Hypersensitivity (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 12
  • # of Trial APIs: 5